Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Foghorn Therapeutics (FHTX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Foghorn Therapeutics (FHTX) had its "outperform" rating reaffirmed by Wedbush. They now have a $10.00 price target on the stock.
Foghorn Therapeutics GAAP EPS of -$1.18 misses by $0.08, revenue of $30.91M misses by $0.31M [Seeking Alpha]